In February of 2006, specialists studying the various Tequin side effects began to call on the FDA to get involved by forcing Bristol-Myers Squibb to provide additional warning information to Tequin users. In essence, an FDA "black box" warning, the strictest drug warning available under FDA regulation, was sought.

On March 1, 2006 the results of a Canadian study were released which indicate that the antibiotic Tequin caused patients who were prescribed the medication to have a 17 times greater risk of developing diabetes. In addition, the study revealed that there was a 4 times greater risk among Tequin users of being hospitalized with low blood sugar disorders. Tequin has also been shown to cause side effects such as liver damage, irregular heartbeats, fainting, muscle damage, dizziness and nausea.

Usage:

Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin. Gatifloxacin was developed with the intention of serving as an oral or intravenous treatment for respiratory tract infections, chronic bronchitis, sinusitis, pneumonia and urinary tract infections.

Litigation:

As a result of the Tequin side effects and continued negative attention, Bristol-Myers Squibb opted to voluntarily halt production of the antibiotic; however, they are not willing to recall all remaining Tequin antibiotics that remain in circulation. It has been decided that sale of all remaining Tequin antibiotics will continue until the existing stockpile has been sold. Numerous public interest groups have been rallying in an attempt to get the FDA to place a ban on all remaining Tequin. As of yet, such a ban has not been issued.

If you or a loved one have experienced serious injury as a result of taking Tequin please fill out the contact form and an experienced DrugSettlement.com attorney or representative will call you to for a free and confidential evaluation of your claim.